邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

绝经激素治疗增加乳腺癌患病风险：Lancet最新文献解读

徐颖,  徐雅莉,  王喆,  林燕,  王常珺,  孙强

downloadPDF
文章导航 > 协和医学杂志  > 2020 >  11(5): 621-625
徐颖, 徐雅莉, 王喆, 林燕, 王常珺, 孙强. 绝经激素治疗增加乳腺癌患病风险：Lancet最新文献解读[J]. 协和医学杂志, 2020, 11(5): 621-625. doi: 10.3969/j.issn.1674-9081.2020.05.020
引用本文: 徐颖, 徐雅莉, 王喆, 林燕, 王常珺, 孙强. 绝经激素治疗增加乳腺癌患病风险：Lancet最新文献解读[J]. 协和医学杂志, 2020, 11(5): 621-625. doi: 10.3969/j.issn.1674-9081.2020.05.020
shu
Ying XU, Ya-li XU, Zhe WANG, Yan LIN, Chang-jun WANG, Qiang SUN. Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 621-625. doi: 10.3969/j.issn.1674-9081.2020.05.020
Citation: Ying XU, Ya-li XU, Zhe WANG, Yan LIN, Chang-jun WANG, Qiang SUN. Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 621-625. doi: 10.3969/j.issn.1674-9081.2020.05.020
shu

绝经激素治疗增加乳腺癌患病风险：Lancet最新文献解读

doi: 10.3969/j.issn.1674-9081.2020.05.020

  • 中国医学科学院 北京协和医学院 北京协和医院乳腺外科，北京 100730

详细信息
    通讯作者:

    孙强 电话: 010-69152700，E-mail: sunqiang@163.com

  • 中图分类号: R737.9

Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019

  • Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Pecking Union Medical College, Beijing 100730, China

More Information

    摘要
  • 摘要: 绝经激素治疗(menopausal hormone therapy, MHT)是否会增加乳腺癌的发病风险一直存在争议。2019年9月，Lancet发表了一篇荟萃分析，汇集了世界范围内关于MHT与乳腺癌发病风险的证据。此研究结果表明，除阴道应用雌激素外，所有方式应用MHT均增加乳腺癌发病风险，且该风险随MHT应用时间的延长逐渐升高。其中雌激素、孕激素联合治疗风险更高，停药后额外风险可持续10年以上。小剂量应用MHT或选择天然孕激素等并不能回避乳腺癌发病风险的增加。本文对该荟萃分析进行解读，强调应用MHT需考虑乳腺癌风险，全面评估患者风险与获益。
    Abstract: Whether menopausal hormone therapy (MHT) increases the risk of breast cancer has been controversial. In September 2019, the famous medical journal, the Lancet, published a meta-analysis that has gathered the worldwide evidence of MHT and incidence of breast cancer, showing that in addition to vaginal estrogen, all type of MHTs increased the risk of breast cancer, and the risk increased steadily with the duration of MHT use. The risk was greater for oestrogen-progestagen therapy; the excess risk persisted after the drug was stopped for more than 10 years. Low doses of MHT or natural progesterone do not prevent the risk of breast cancer. This article interprets the meta-analysis and emphasizes that MHT should be taken into account of increasing the risk of breast cancer, and the risks and benefits should be fully evaluated.
    利益冲突  无
    • HTML全文
    • 参考文献(28)
  • [1] Lindsey A, Freddie Bray T, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65:87-108. doi:  10.3322/caac.21262
    [2] Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010[J]. Br J Cancer, 2011, 105:S77-S81. doi:  10.1038/bjc.2011.489
    [3] Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial[J]. JAMA, 2002, 288:321-333. doi:  10.1001/jama.288.3.321
    [4] Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial[J]. JAMA, 2003, 289:3243-3253. doi:  10.1001/jama.289.24.3243
    [5] Beral V, Reeves G, Bull D, et al. Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy[J]. J Natl Cancer Inst, 2011, 103:296-305. doi:  10.1093/jnci/djq527
    [6] Stahlberg C, Pedersen AT, Andersen ZJ, et al. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy[J]. Br J Cancer, 2004, 91:644-650. doi:  10.1038/sj.bjc.6601996
    [7] Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort[J]. Int J cancer, 2005, 114:448-454. doi:  10.1002/ijc.20710
    [8] Roman M, Sakshaug S, Graff-Iversen S, et al. Postmenopausal hormone therapy and the risk of breast cancer in Norway[J]. Int J Cancer, 2016, 138:584-593. doi:  10.1002/ijc.29810
    [9] Jones ME, Schoemaker MJ, Wright L, et al. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?[J].Br J Cancer, 2016, 115:607-615. doi:  10.1038/bjc.2016.231
    [10] Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials[J]. JAMA Oncol, 2015, 1:296-305. doi:  10.1001/jamaoncol.2015.0494
    [11] Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, et al. hormone replacement therapy and breast cancer risk: A cohort study of 16 928 women 48 years and older[J]. Acta Oncol, 2014, 53:752-758. doi:  10.3109/0284186X.2013.878471
    [12] Fournier A, Mesrine S, Dossus L, et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment[J]. Breast Cancer Res Treat, 2014, 145:535-543. doi:  10.1007/s10549-014-2934-6
    [13] Pizot C, Boniol M, Mullie P, et al. Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies[J]. Eur J Cancer, 2016, 52:138-154. doi:  10.1016/j.ejca.2015.10.063
    [14] Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis[J]. Lancet Oncol, 2006, 7:910-918. doi:  10.1016/S1470-2045(06)70911-1
    [15] Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials[J]. Hum Reprod Update, 2005, 11:561-573. doi:  10.1093/humupd/dmi031
    [16] Manson JE, Chlebowski RT, Stefanick ML, et al. The Women's Health Initiative Hormone Therapy Trials: Update and Overview of Health Outcomes During the Intervention and Post-Stopping Phases[J]. JAMA, 2013, 301:1353-1368. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1177/0148607102026001011
    [17] Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women[J].N Engl J Med, 2008, 14, 359: 697-708. doi:  10.1097/01.ogx.0000338097.79940.0c
    [18] Chlebowski RT, Anderson GL, Aragaki AK, et al.Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index[J]. J Nat Cancer Inst, 2016;108. http://www.ncbi.nlm.nih.gov/pubmed/26546117
    [19] Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence[J]. Lancet, 2019, 394:1159-1168. doi:  10.1016/S0140-6736(19)31709-X
    [20] Munsell MF, Sprague BL, Berry DA, et al. Body Mass Index and Breast Cancer Risk According to Postmenopausal Estrogen- Progestin Use and Hormone Receptor Status[J]. Epidemiol Rev, 2014, 36:114-136. doi:  10.1093/epirev/mxt010
    [21] Wang K, Li F, Chen L, et al.Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies[J].Oncotarget, 2017, 8:81109-81124. doi:  10.18632/oncotarget.20154
    [22] Maas P, Barrdahl M, Joshi AD, et al. Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States[J]. JAMA Oncol, 2016, 2:1295-1302. doi:  10.1001/jamaoncol.2016.1025
    [23] 徐颖, 林燕, 王常珺, 等.共识与争议:绝经激素治疗与乳腺癌发病风险[J].协和医学杂志, 2018, 9:332-335. https://mjpumch.cbpt.cnki.net/WKC3/WebPublication/paperDigest.aspx?paperID=d455fd28-6dbd-4caf-abc7-c61a7faf1ebc

    Xu Y, Lin Y, Wang CJ, et al. Consensus and Controversy: Menopausal Hormone Therapy and the Risk of Breast Carcinoma[J]. Med J PUMCH, 2018, 9:332-335. https://mjpumch.cbpt.cnki.net/WKC3/WebPublication/paperDigest.aspx?paperID=d455fd28-6dbd-4caf-abc7-c61a7faf1ebc
    [24] Saxena T, Lee E, Henderson KD, et al.Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19:2366-2378. doi:  10.1158/1055-9965.EPI-10-0162
    [25] Simin J, Tamimi R, Lagergren J, et al. Menopausal hormone therapy and cancer risk: An overestimated risk?[J]. Eur J Cancer, 2017, 84:60-68. doi:  10.1016/j.ejca.2017.07.012
    [26] Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study[J].Lancet, 2003, 362: 419-427. doi:  10.1016/S0140-6736(03)14065-2
    [27] Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol 2014, 15:e279-e289. doi:  10.1016/S1470-2045(13)70567-9
    [28] LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a random-ized controlled trial[J]. JAMA, 2011, 305:1305-1314. doi:  10.1001/jama.2011.382
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  231
  • HTML全文浏览量:  29
  • PDF下载量:  46
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-11-18
  • 刊出日期:  2020-09-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！